Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer

被引:0
|
作者
Candelieri-Surette, Danielle [1 ]
Hung, Anna [2 ,3 ,4 ]
Lynch, Julie A. [1 ,5 ,6 ]
Pridgen, Kathryn M. [1 ,5 ]
Agiri, Fatai Y. [1 ]
Li, Weiyan [7 ]
Aggarwal, Himani
Anglin-Foote, Tori [1 ,5 ]
Lee, Kyung Min [1 ]
Perez, Cristina [1 ]
Reed, Shelby [2 ,3 ,4 ]
DuVall, Scott L. [1 ,5 ]
Wong, Yu-Ning [8 ,9 ]
Alba, Patrick R. [1 ,5 ]
机构
[1] VA Salt Lake City Hlth Care Syst, VA Informat & Comp Infrastruct, Salt Lake City, UT USA
[2] Durham VA Med Ctr, Durham, NC USA
[3] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[4] Duke Univ, Sch Med, Dept Populat Hlth Sci, Durham, NC USA
[5] Univ Utah, Sch Med, Div Epidemiol, Dept Internal Med, Salt Lake City, UT USA
[6] Univ Massachusetts, Dept Nursing & Hlth Sci, Boston, MA USA
[7] AstraZenca Pharmaceut LP, Gaithersburg, MD USA
[8] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA USA
来源
关键词
CLINICAL-TRIALS; RECOMMENDATIONS; DESIGN;
D O I
10.1200/CCI.23.00085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Several novel therapies for castration-resistant prostate cancer (CRPC) have been approved with randomized phase III studies with continuing observational research either planned or ongoing. Accurately identifying patients with CRPC in electronic health care data is critical for quality observational research, resource allocation, and quality improvement. Previous work in this area has relied on either structured laboratory results and medication data or natural language processing (NLP) methods. However, a computable phenotype using both structured data and NLP identifies these patients with more accuracy. METHODS The Corporate Data Warehouse (CDW) of the Veterans Health Administration (VHA) was used to collect PCa diagnoses, prostate-specific antigen test results, and information regarding patient characteristics and medication use. The final system used for validation and subsequent analysis combined the NLP system and an algorithm of structured laboratory and medication data to identify patients as being diagnosed with CRPC. Patients with both a documented diagnosis of CRPC and a documented diagnosis of metastatic PCa were classified as having mCRPC by this system. RESULTS Among 1.2 million veterans with PCa, the International Classification of Diseases (ICD)-10 diagnosis code for CRPC (Z19.2) identifies 3,791 patients from 2016 when the code was created until 2022, compared with the combined algorithm which identifies 14,103, 10,312 more than ICD-10 codes alone, from 2016 to 2022. The combined algorithm showed a sensitivity of 97.9% and a specificity of 99.2%. CONCLUSION ICD-10 codes proved to be insufficient for capturing CRPC in the VHA CDW data. Using both structured and unstructured data identified more than double the number of patients compared with ICD-10 codes alone. Application of this combined approach drastically improved identification of real-world patients and enables high-quality observational research in mCRPC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer
    Candelieri-Surette, Danielle
    Hung, Anna
    Lynch, Julie A.
    Pridgen, Kathryn M.
    Agiri, Fatai Y.
    Li, Weiyan
    Aggarwal, Himani
    Anglin-Foote, Tori
    Lee, Kyung Min
    Perez, Cristina
    Reed, Shelby
    Duvall, Scott L.
    Wong, Yu-Ning
    Alba, Patrick R.
    [J]. JCO CLINICAL CANCER INFORMATICS, 2023, 7
  • [2] Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
    Watahiki, Akira
    Macfarlane, Robyn J.
    Gleave, Martin E.
    Crea, Francesco
    Wang, Yuzhuo
    Helgason, Cheryl D.
    Chi, Kim N.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 7757 - 7770
  • [3] Enzalutamide for Patients with castration-resistant Prostate Cancer
    Kessing, Richard
    [J]. AKTUELLE UROLOGIE, 2020, 51 (01)
  • [4] Cabazitaxel in patients with castration-resistant prostate cancer
    Falcao, Gil
    Carneiro, Cabrita
    Pinheiro, Luis Campos
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 25 - 25
  • [5] DIETHYLSTILBESTROL IN CASTRATION-RESISTANT PROSTATE CANCER OESTROGENS IN CASTRATION-RESISTANT PROSTATE CANCER: BACK TO THE FUTURE?
    Sartor, Oliver
    [J]. BJU INTERNATIONAL, 2012, 110 (11B) : E736 - E736
  • [6] Multistage, long-term therapy for patients diagnosed with castration-resistant prostate cancer
    Majecka-Kotwica, Malgorzata
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 : C13 - C15
  • [7] Macrophage Regulation of the Development of Castration-Resistant Prostate Cancer
    Al-Janabi, Haider
    Lewis, Claire E.
    [J]. CANCER RESEARCH, 2021, 81 (21) : 5399 - 5400
  • [8] The development of abiraterone acetate for castration-resistant prostate cancer
    Grist, Emily
    Attard, Gerhardt
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (06) : 289 - 294
  • [9] Development of enzalutamide for metastatic castration-resistant prostate cancer
    Bhattacharya, Suman
    Hirmand, Mohammad
    Phung, De
    van Os, Steve
    [J]. PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
  • [10] Development and prevalence of castration-resistant prostate cancer subtypes
    Vellky, Jordan E.
    Ricke, William A.
    [J]. NEOPLASIA, 2020, 22 (11): : 566 - 575